Literature DB >> 36242728

LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.

Jianwu Long1,2, Longfei Liu1, Xuefeng Yang3, Xiaojun Zhou1, Xianzhou Lu4, Lei Qin5.   

Abstract

Emerging evidence has uncovered that noncoding RNAs (ncRNAs) contribute to the development of hepatocellular carcinoma (HCC). Nevertheless, the functions of the majority of long ncRNAs (lncRNAs) in HCC are unknown. Here, we intend to probe the function of lncRNA NUTM2A-AS1 in the evolvement of HCC and the related mechanism. Expression levels of lncRNA NUTM2A-AS1, miR-186-5p and KLF7 mRNA in HCC tissues and adjacent non-tumor tissues were monitored. Gain- or loss-of-function assays were utilized to investigate the biological functions of lncRNA NUTM2A-AS1, miR-186-5p and KLF7 in HCC cell lines (including HCCLM3 and Huh7). Western blot was implemented for the detection of the epithelial-mesenchymal transition (EMT)-related proteins (including E-cadherin, Vimentin and Snail), KLF7, Wnt, β-catenin, and stemness-related proteins (Nanog, OCT4, YKL40, and CD133). Furthermore, the targeted associations between lncRNA NUTM2A-AS1, miR-186-5p, and KLF7 were verified by bioinformatics analysis, dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. As a result, lncRNA NUTM2A-AS1 and KLF7 profiles were heightened in the HCC tissues versus adjacent normal tissues, while miR-186-5p had the opposite expression tendency. Up-regulation of lncRNA NUTM2A-AS1 was related to tumor size, advanced tumor stage, and lymph node metastasis of HCC patients. Functionally, overexpression of lncRNA NUTM2A-AS1 heightened HCC cells' growth, invasion, EMT, and stemness and repressed their apoptosis by activating the Wnt/β-catenin pathway. In contrast, up-regulation of miR-186-5p or inhibition of KLF7 had reverse effects. In vivo, lncRNA NUTM2A-AS1 overexpression facilitated tumor growth and EMT, accompanied by declined miR-186-5p levels and enhanced KLF7 expression. The mechanistic studies revealed that miR-186-5p served as a common target of lncRNA NUTM2A-AS1 and KLF7. As hinted by the rescue experiments, NUTM2A-AS1 partly abated miR-186-5p-mediated anti-tumor effects in HCC cells, whereas KLF7 knockdown reversed the promotive effects of NUTM2A-AS1. LncRNA NUTM2A-AS1 accelerated the evolution of HCC by up-regulating the KLF7/Wnt/beta-catenin pathway through sponging miR-186-5p.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  Competing endogenous RNA; Hepatocellular carcinoma; LncRNA NUTM2A-AS1; miR-186-5p

Year:  2022        PMID: 36242728     DOI: 10.1007/s13577-022-00802-5

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  37 in total

1.  miR-186-5p Functions as a Tumor Suppressor in Human Osteosarcoma by Targeting FOXK1.

Authors:  Zhiqiang Zhang; Wen Zhang; Junsheng Mao; Zheng Xu; Mingyu Fan
Journal:  Cell Physiol Biochem       Date:  2019

Review 2.  [Current treatment in advanced hepatocellular carcinoma and prospects for immuno-oncology therapy].

Authors:  J M Xu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2017-08-23

3.  A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.

Authors:  Xiaoyan Xu; Yumeng Wang; Kamalika Mojumdar; Zhicheng Zhou; Kang Jin Jeong; Lingegowda S Mangala; Shuangxing Yu; Yiu Huen Tsang; Cristian Rodriguez-Aguayo; Yiling Lu; Gabriel Lopez-Berestein; Anil K Sood; Gordon B Mills; Han Liang
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

4.  miR-186-5p promotes cell growth, migration and invasion of lung adenocarcinoma by targeting PTEN.

Authors:  Hongxiang Feng; Zhenrong Zhang; Xin Qing; Samuel W French; Deruo Liu
Journal:  Exp Mol Pathol       Date:  2019-04-11       Impact factor: 3.362

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 6.  Immunotherapy for hepatocellular carcinoma.

Authors:  Shuzhan Li; Fan Yang; Xiubao Ren
Journal:  Drug Discov Ther       Date:  2015-10

Review 7.  Hepatocellular carcinoma: From diagnosis to treatment.

Authors:  Miral Sadaria Grandhi; Amy K Kim; Sean M Ronnekleiv-Kelly; Ihab R Kamel; Mounes A Ghasebeh; Timothy M Pawlik
Journal:  Surg Oncol       Date:  2016-03-05       Impact factor: 3.279

8.  The landscape of long noncoding RNAs in the human transcriptome.

Authors:  Matthew K Iyer; Yashar S Niknafs; Rohit Malik; Udit Singhal; Anirban Sahu; Yasuyuki Hosono; Terrence R Barrette; John R Prensner; Joseph R Evans; Shuang Zhao; Anton Poliakov; Xuhong Cao; Saravana M Dhanasekaran; Yi-Mi Wu; Dan R Robinson; David G Beer; Felix Y Feng; Hariharan K Iyer; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2015-01-19       Impact factor: 38.330

9.  Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis.

Authors:  Amelia Acha-Sagredo; Bubaraye Uko; Paschalia Pantazi; Naiara G Bediaga; Chryssanthi Moschandrea; Lucille Rainbow; Michael W Marcus; Michael P A Davies; John K Field; Triantafillos Liloglou
Journal:  Br J Cancer       Date:  2020-02-05       Impact factor: 7.640

10.  LncRNA NUTM2A-AS1 positively modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR-376a.

Authors:  Ji Wang; Ziyang Yu; Jun Wang; Yidan Shen; Junlan Qiu; Zhixiang Zhuang
Journal:  Cancer Med       Date:  2020-10-22       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.